Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

$MRNS
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $MRNS alert in real time by email
SC 13G/A 1 eventide_marinus-sc13ga.htm SC 13G/A

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Marinus Pharmaceuticals, Inc.

(Name of Issuer – as specified in its charter)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

56854Q200

(CUSIP Number)

September 30, 2024

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

þ       Rule 13d-1(b)

¨        Rule 13d-1(c)

¨        Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 
 

 

1

NAME OF REPORTING PERSON

Eventide Asset Management, LLC

 

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

¨ (a)

¨ (b)

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

5

SOLE VOTING POWER

0

 

6

SHARED VOTING POWER

0

7

SOLE DISPOSITIVE POWER

0

 

8

SHARED DISPOSITIVE POWER

0

 

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0

 

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

¨

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0.00%

 

12

TYPE OF REPORTING PERSON

IA

       

 

 
 

 

1

NAME OF REPORTING PERSON

Finny Kuruvilla, M.D. Ph. D.

 

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

¨ (a)

¨ (b)

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

5

SOLE VOTING POWER

0

 

6

SHARED VOTING POWER

0

 

7

SOLE DISPOSITIVE POWER

0

 

8

SHARED DISPOSITIVE POWER

0

 

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0

 

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

¨

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0.00%

 

12

TYPE OF REPORTING PERSON

IN;HC

       

 

 
 

 

1

NAME OF REPORTING PERSON

Robin C. John

 

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

¨ (a)

¨ (b)

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

5

SOLE VOTING POWER

0

 

6

SHARED VOTING POWER

0

 

7

SOLE DISPOSITIVE POWER

0

 

8

SHARED DISPOSITIVE POWER

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0

 

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

¨

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0.00%

 

12

TYPE OF REPORTING PERSON

IN;HC

       

 

 
 

Item 1. (a) Name of Issuer:

Marinus Pharmaceuticals, Inc. (the “Issuer”)

(b) Address of Issuer’s Principal Executive Offices:

5 Radnor Corporate Center, Suite 500, 100 Matsonford Rd, Radnor, PA 19087

Item 2. (a) Name of Persons Filing:

(i) Eventide Asset Management, LLC (“Eventide”)

(ii) Finny Kuruvilla, M.D., Ph.D. (“Kuruvilla”)

(iii) Robin C. John (“John”)

(b). Address of Principal Business Office or, if none, Residence:

Eventide, Kuruvilla and John:

One International Place, Suite 4210

Boston, Massachusetts 02110

(c). Citizenship or Place of Organization:

Eventide: Delaware

Kuruvilla: United States

John: United States

(d). Title of Class of Securities:

Common Stock, par value $0.001 per share

 

(e). CUSIP Number:

56854Q200

Item 3. If this statement is filed pursuant to sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) [x] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with section 240.13d- 1(b)(1)(ii)(F);

(g) [x] A parent holding company or control person in accordance with section 240.13d- 1(b)(1)(ii)(G);

(h) [ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance

Act (12 U.S.C. 1813);

 
 

(i) [ ] A church plan that is excluded from the definition of an investment company under

section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J);

 

(k) [ ] A group, in accordance with section 240.13d-1(b)(1) (ii)(K).

If filing as a non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

Item 4. Ownership:

Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

(a). Amount beneficially owned:

(i) Eventide: 0

(ii) Kuruvilla: 0

(iii) John: 0

(b). Percent of class:

(i) Eventide: 0.00%

(ii) Kuruvilla: 0.00%

(iii) John: 0.00%

(c). Number of shares as to which the person has:

(i)        Sole power to vote or to direct the vote:

(1) Eventide: 0

(2) Kuruvilla: 0

(3) John: 0

(ii)        Shared power to vote or to direct the vote:

 

(1) Eventide: 0

(2) Kuruvilla: 0

(3) John: 0

(iii) Sole power to dispose or to direct the disposition of:

(1) Eventide: 0

(2) Kuruvilla: 0

(3) John: 0

(iv) Shared power to dispose or to direct the disposition of:

(1) Eventide: 0

(2) Kuruvilla: 0

(3) John: 0

 
 

Item 5. Ownership of Five Percent or Less of a Class:

This statement is being filed to report the fact that as of the date hereof Eventide Asset Management, LLC has ceased to be the beneficial owner of more than five percent of the Issuer’s outstanding Common Stock.

Item 6.Ownership of More Than Five Percent on Behalf of Another Person:

Not Applicable

Item 7.Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company:

Not Applicable

Item 8. Identification and Classification of Members of the Group:

Not Applicable

Item 9. Notice of Dissolution of Group:

Not Applicable

Item 10.Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

 
 

SIGNATURES

 

The undersigned certify, after reasonable inquiry and to the best knowledge and belief of the undersigned, that the information set forth in this Statement is true, complete and correct. The undersigned agree to the filing of this single Statement on Schedule 13G.

 

Eventide Asset Management, LLC

Date: November 11, 2024 By: /s/ Peter J. Luiso

Name: Peter J. Luiso

Title: General Counsel

 

 

Finny Kuruvilla, M.D., Ph. D.

Date: November 11, 2024 By: /s/ Finny Kuruvilla, M.D., Ph. D.

Name: Finny Kuruvilla, M.D., Ph. D.

Robin C. John

Date: November 11, 2024 By: /s/ Robin C. John

Name: Robin C. John

 
 

 

EXHIBIT 1

WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto is filed on behalf of each of them;

NOW, THEREFORE, the parties hereto agree as follows:

Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph. D. and Robin C. John do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file a Statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Statement on Schedule 13G shall be filed on behalf of each of them.

Eventide Asset Management, LLC

Date: November 11, 2024

By: /s/ Peter J. Luiso

Name: Peter J. Luiso

Title: General Counsel

 

 

Finny Kuruvilla, M.D., Ph. D.

Date: November 11, 2024

By: /s/ Finny Kuruvilla, M.D., Ph. D.

Name: Finny Kuruvilla, M.D., Ph. D.

Robin C. John

Date: November 11, 2024

By: /s/ Robin C. John

Name: Robin C. John

Get the next $MRNS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MRNS

DatePrice TargetRatingAnalyst
9/23/2024$6.00Perform → Outperform
Oppenheimer
8/14/2024Buy → Neutral
Ladenburg Thalmann
4/16/2024$20.00 → $2.00Outperform → Neutral
Robert W. Baird
4/15/2024$24.00 → $3.00Outperform → Sector Perform
RBC Capital Mkts
8/11/2023$14.00 → $9.00Outperform → Perform
Oppenheimer
1/20/2023$23.00Outperform
RBC Capital Mkts
12/20/2021$32.00 → $30.00Outperform
SVB Leerink
More analyst ratings

$MRNS
Press Releases

Fastest customizable press release news feed in the world

See more
  • Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

    Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company committed to improving the lives of patients with seizure disorders, today announced that they have entered into an agreement and plan of merger under which Immedica has agreed to acquire Marinus, by means of a tender offer and subsequent merger. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241230307666/en/ The acquisition complements and further strengthens Immedica's global rare disease business by adding ZTALMY® (ganaxalone) oral suspension, CV, a neuroactive steroid gamma-aminobuty

    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

    ZTALMY® (ganaxolone) Q3 2024 net product revenue of $8.5 million representing growth of 56% versus Q3 2023 Narrowing full year 2024 ZTALMY net product revenue guidance to $33 to $34 million Reported results from Phase 3 TrustTSC trial and commenced process to explore strategic alternatives Marinus continues to support the commercial growth of ZTALMY; further ganaxolone clinical development has been suspended Scheduled to meet with FDA Q4 2024 to discuss a potential path forward for IV ganaxolone in refractory status epilepticus Cost reduction plans implemented with cash runway expected into Q2 2025; cash and cash equivalents of $42.2 million as of September 30, 2024 Marin

    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

    Trial did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency (p=0.09); results showed numerically higher response rates for ganaxolone than placebo Ganaxolone was generally well-tolerated in TrustTSC with a safety profile consistent with previous clinical trials Cost reduction activities are underway Marinus has engaged Barclays as an advisor to assist with evaluating strategic alternatives Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Phase 3 TrustTSC trial evaluating oral ganaxolone for the treatment of seizures as

    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MRNS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MRNS
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$MRNS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MRNS
SEC Filings

See more

$MRNS
Leadership Updates

Live Leadership Updates

See more
  • DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

    Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh

    $DMAC
    $MRNS
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.

    Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors. "Sarah is an accomplished healthcare executive with extensive global clinical development and corporate strategy experience," said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. "With a track record of successfully advancing programs in various therapeutic areas using diverse modalities, a deep understanding of orphan diseases and over a decade of experience as a hospitalist physician, her unique perspective will be invalu

    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors

    Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Marvin H. Johnson, Jr. to its Board of Directors. "With over 34 years of diverse commercial operations experience at Merck & Co., we are delighted that Marvin is joining the Marinus Board," said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. "His impressive background launching products across multiple therapeutic categories, including neurology and acute care, will be invaluable in supporting the continued commercial success of ZTALMY® and in preparing for a potential hospital

    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MRNS
Financials

Live finance-specific insights

See more
  • Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

    ZTALMY® (ganaxolone) Q2 2024 net product revenue of $8.0 million representing strong growth of 87% versus Q2 2023 On track to achieve full year 2024 ZTALMY net product revenue guidance of between $33 and $35 million Completed enrollment in the Phase 3 TrustTSC trial of oral ganaxolone in tuberous sclerosis complex (TSC) with topline data expected in the first half of Q4 2024 Expanded ZTALMY global footprint with activation of managed access programs for MENA, Russia and Canada with upcoming commercial launches anticipated in Europe and China Succeeded in post-grant review challenge of Ovid Therapeutics' U.S. Patent 11,395,817 for IV ganaxolone in the treatment of status epilept

    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Ligand Reports Second Quarter 2024 Financial Results

    Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

    $AGEN
    $AMGN
    $CASI
    $LGND
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024

    Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will host a conference call at 8:30 a.m. E.T. on August 13, 2024, to provide a business update and discuss financial results. Tuesday, August 13, 8:30 a.m. E.T. Domestic: (877) 405-1242 International: (201) 389-0852 Webcast Registration: Click Here An archived version of the call will be available approximately two hours after the completion of the event on the Marinus website at ir.marinuspharma.com/e

    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MRNS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more